{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:22:38Z","timestamp":1791840158382,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"IRCCS San Gerardo"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtct.2025.05.021","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T12:19:43Z","timestamp":1748261983000},"page":"699.e1-699.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Letermovir Primary and Secondary Prophylaxis in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplant"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-793X","authenticated-orcid":false,"given":"Francesca","family":"Vendemini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro Maria Ivano","family":"Malandrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-6202","authenticated-orcid":false,"given":"Marta","family":"Verna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bonanomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.05.021_bib0001","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.15515","article-title":"Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis","volume":"19","author":"Gim\u00e9nez","year":"2019","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jtct.2025.05.021_bib0002","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft versus- host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.021_bib0003","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.021_bib0004","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/pbc.25237","article-title":"Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"62","author":"Qayed","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2025.05.021_bib0005","first-page":"6551","article-title":"Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: proposal for classification","volume":"37","author":"Dziedzic","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtct.2025.05.021_bib0006","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.021_bib0007","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1056\/NEJM199104113241509","article-title":"Preemptive therapy in immunocompromised hosts","volume":"324","author":"Rubin","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.05.021_bib0008","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2025.05.021_bib0009","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.021_bib0010","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.bbmt.2018.05.017","article-title":"Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneicn hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"24","author":"Gagelmann","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.jtct.2025.05.021_bib0011","unstructured":"US Food and Drug Administration. PREVYMIS (letermovir) tablets and PREVYMIS (letermovir) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209939Orig1s000,209940Orig1s000TOC.cfm."},{"key":"10.1016\/j.jtct.2025.05.021_bib0012","unstructured":"European Medicines Agency. Prevymis (letermovir).http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl5pages\/medicines\/human\/medicines\/004536\/human_med_002200.jsp&mid5WC0b01ac058001d124."},{"issue":"25","key":"10.1016\/j.jtct.2025.05.021_bib0013","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.021_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of letermovir for cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.021_bib0015","doi-asserted-by":"crossref","first-page":"62.e1","DOI":"10.1016\/j.jtct.2022.10.005","article-title":"Letermovir as cytomegalovirus prophylaxis in a pediatric cohort: a retrospective analysis","volume":"29","author":"Kuhn","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.05.021_bib0016","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.21873\/anticanres.15848","article-title":"Letermovir prophylaxis for cytomegalovirus infection in children after hematopoietic cell transplantation","volume":"42","author":"Richert-Przygonska","year":"2022","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.021_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jmii.2022.01.002","article-title":"Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan","volume":"55","author":"Cheng","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.021_bib0018","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41409-020-01166-w","article-title":"Use of letermovir in off-label indications: infectious diseases working party of european society of blood and marrow transplantation retrospective study","volume":"56","author":"Styczy\u0144ski","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.021_bib0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40272-022-00547-6","article-title":"Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients","volume":"25","author":"K\u00f6rholz","year":"2023","journal-title":"Paediatr Drugs"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.021_bib0020","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/jac\/dkz218","article-title":"Letermovir in paediatric HSCT recipients","volume":"74","author":"Strenger","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.021_bib0021","first-page":"96","article-title":"Compassionate use of letermovir in a 2-year-old immunocompromised child with resistant cytomegalovirus disease","volume":"9","author":"P\u00e9rez Mar\u00edn","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"7","key":"10.1016\/j.jtct.2025.05.021_bib0022","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jpids\/piac017","article-title":"Letermovir for cytomegalovirus prevention in adolescent patients following hematopoietic cell transplantation","volume":"11","author":"Daukshus","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jtct.2025.05.021_bib0023","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2147\/IDR.S296927","article-title":"Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant","volume":"14","author":"Chiereghin","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.021_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30608","article-title":"Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation","volume":"70","author":"Chen","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.021_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10875-023-01617-1","article-title":"Letermovir for CMV prophylaxis in very high-risk pediatric hematopoietic stem cell transplantation recipients for inborn errors of immunity","volume":"44","author":"C\u00e9sar","year":"2023","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.021_bib0026","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","article-title":"Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)","volume":"59","author":"Galaverna","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.021_bib0027","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1248\/bpb.b24-00217","article-title":"Letermovir at a prophylactic dose for cytomegalovirus infection in children undergoing allogeneic hematopoietic stem cell transplantation: a single-center retrospective study in Japan","volume":"47","author":"Tatebe","year":"2024","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.021_bib0028","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/jcph.1423","article-title":"Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil","volume":"59","author":"McCrea","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2025.05.021_bib0029","unstructured":"EBMT Handbook 2024"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.021_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106220","article-title":"Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study","volume":"89","author":"Hopff","year":"2024","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.021_bib0031","doi-asserted-by":"crossref","first-page":"85.e1","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2025.05.021_bib0032","doi-asserted-by":"crossref","first-page":"510.e1","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.021_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13866","article-title":"Clinical \u201creal-world\u201d experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","volume":"34","author":"Anderson","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2025.05.021_bib0034","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.021_bib0035","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.021_bib0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.021_bib0037","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41409-024-02376-2","article-title":"Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis","volume":"59","author":"Esteve","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.05.021_bib0038","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.021_bib0039","article-title":"Pharmacoeconomic Review Report: Letermovir (Prevymis): (Merck Canada Inc.): Indication: For the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients (R+) of an allogeneic hematopoietic stem cell transplant [Internet]","year":"2018","journal-title":"Ottawa (ON): Canadian Agency for Drugs and Technologies in Health"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.021_bib0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s41669-023-00398-y","article-title":"Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States","volume":"7","author":"Sepassi","year":"2023","journal-title":"Pharmacoecon Open"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:32:41Z","timestamp":1756211561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666636725012059"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir Primary and Secondary Prophylaxis in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}